Literature DB >> 30079443

Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Chongchong Wang1, Juehua Jing2, Li Cheng3.   

Abstract

Non-coding RNAs (ncRNAs) have been found to play essential roles in various physiological and pathological processes. The involvement of ncRNAs in the development of osteosarcoma (OS) has been explored in recent years. In this review, we summarize the functions and mechanisms of microRNA, lncRNA and circRNA in the initiation and progression of OS. We specifically focused on their potential application in the diagnosis, prognosis and therapy of OS. This summary of current knowledge on the involvement of ncRNAs in OS will not only aid comprehension of the complex processes of OS initiation and progression but also contribute to the exploration of ideal diagnostic biomarkers and therapeutic targets for OS patients.

Entities:  

Keywords:  Long non-coding RNAs; Osteosarcoma; circRNAs; microRNAs

Mesh:

Substances:

Year:  2018        PMID: 30079443     DOI: 10.1007/s10637-018-0624-7

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  198 in total

1.  MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.

Authors:  J Lu; G Song; Q Tang; J Yin; C Zou; Z Zhao; X Xie; H Xu; G Huang; J Wang; D-F Lee; R Khokha; H Yang; J Shen
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

Review 2.  Nanocarriers for microRNA delivery in cancer medicine.

Authors:  I Fernandez-Piñeiro; I Badiola; A Sanchez
Journal:  Biotechnol Adv       Date:  2017-03-08       Impact factor: 14.227

Review 3.  MicroRNA-associated carcinogenesis in lung carcinoma.

Authors:  Pushpendra Pratap; Syed Tasleem Raza; Shania Abbas; Farzana Mahdi
Journal:  J Cancer Res Ther       Date:  2018 Jan-Mar       Impact factor: 1.805

4.  Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.

Authors:  Nai-Guo Wang; Da-Chuan Wang; Bing-Yi Tan; Feng Wang; Ze-Nong Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 5.  MicroRNA-Based Drugs for Brain Tumors.

Authors:  Shubaash Anthiya; Audrey Griveau; Claire Loussouarn; Patrick Baril; Martin Garnett; Jean-Paul Issartel; Emmanuel Garcion
Journal:  Trends Cancer       Date:  2018-02-09

6.  Oleanolic acid induces osteosarcoma cell apoptosis by inhibition of Notch signaling.

Authors:  Ying Xu; Bing Shu; Ye Tian; Guangxi Wang; Yongjun Wang; Jinwu Wang; Yufeng Dong
Journal:  Mol Carcinog       Date:  2018-04-06       Impact factor: 4.784

Review 7.  Circular RNA participates in the carcinogenesis and the malignant behavior of cancer.

Authors:  Zhen-Jun Zhao; Jun Shen
Journal:  RNA Biol       Date:  2015-12-09       Impact factor: 4.652

Review 8.  Targeting immunosuppressive adenosine in cancer.

Authors:  Dipti Vijayan; Arabella Young; Michele W L Teng; Mark J Smyth
Journal:  Nat Rev Cancer       Date:  2017-10-23       Impact factor: 60.716

Review 9.  Natural compounds targeting major cell signaling pathways: a novel paradigm for osteosarcoma therapy.

Authors:  Pablo Angulo; Gaurav Kaushik; Dharmalingam Subramaniam; Prasad Dandawate; Kathleen Neville; Katherine Chastain; Shrikant Anant
Journal:  J Hematol Oncol       Date:  2017-01-07       Impact factor: 17.388

Review 10.  PTEN/PTENP1: 'Regulating the regulator of RTK-dependent PI3K/Akt signalling', new targets for cancer therapy.

Authors:  Nahal Haddadi; Yiguang Lin; Glena Travis; Ann M Simpson; Najah T Nassif; Eileen M McGowan
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

View more
  28 in total

1.  miR-376a inhibits the proliferation and invasion of osteosarcoma by targeting FBXO11.

Authors:  Qiaolong Xu; Li Cheng; Jianyang Chen; Wenjie Lu; Peinian Wang
Journal:  Hum Cell       Date:  2019-05-11       Impact factor: 4.174

Review 2.  MicroRNAs in Bone Metastasis.

Authors:  Eric Hesse; Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2019-06       Impact factor: 5.096

3.  Identification of Osteosarcoma Metastasis-Associated Gene Biomarkers and Potentially Targeted Drugs Based on Bioinformatic and Experimental Analysis.

Authors:  Ming-De Cao; Yan-Cheng Song; Zhong-Meng Yang; Da-Wei Wang; Yi-Ming Lin; Hua-Ding Lu
Journal:  Onco Targets Ther       Date:  2020-08-14       Impact factor: 4.147

4.  Nifuroxazide induces apoptosis, inhibits cell migration and invasion in osteosarcoma.

Authors:  Yi Luo; Anqi Zeng; Aiping Fang; Linjiang Song; Chen Fan; Chenjuan Zeng; Tinghong Ye; Hao Chen; Chongqi Tu; Yongmei Xie
Journal:  Invest New Drugs       Date:  2019-01-25       Impact factor: 3.850

5.  Blocking circ-CNST suppresses malignant behaviors of osteosarcoma cells and inhibits glycolysis through circ-CNST-miR-578-LDHA/PDK1 ceRNA networks.

Authors:  Rui Hu; Shan Chen; Jianxin Yan
Journal:  J Orthop Surg Res       Date:  2021-05-07       Impact factor: 2.359

6.  LINC00665 Facilitates the Malignant Processes of Osteosarcoma by Increasing the RAP1B Expression via Sponging miR-708 and miR-142-5p.

Authors:  Limin Wang; Xinghua Song; Lijun Yu; Bing Liu; Jinfeng Ma; Weihua Yang
Journal:  Anal Cell Pathol (Amst)       Date:  2021-07-07       Impact factor: 2.916

Review 7.  Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.

Authors:  Claudia Maria Hattinger; Maria Pia Patrizio; Silvia Luppi; Massimo Serra
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

8.  MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma.

Authors:  Weixin Xie; Jie Xiao; Tao Wang; Dongmei Zhang; Zhanchun Li
Journal:  J Cell Mol Med       Date:  2019-02-17       Impact factor: 5.310

9.  DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway.

Authors:  Dan Guo; Yarui Li; Yifei Chen; Dan Zhang; Xin Wang; Guifang Lu; Mudan Ren; Xinlan Lu; Shuixiang He
Journal:  Cell Prolif       Date:  2019-04-30       Impact factor: 6.831

10.  LINC00992 contributes to the oncogenic phenotypes in prostate cancer via targeting miR-3935 and augmenting GOLM1 expression.

Authors:  Jianheng Chen; Xiaodong Liu; Kunbin Ke; Jianan Zou; Zhan Gao; Tomonori Habuchi; Xuezhen Yang
Journal:  BMC Cancer       Date:  2020-08-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.